FORWARDED FROM THE CDC BY THE DELAWARE DIVISION OF PUBLIC HEALTH
This is an official
CDC HEALTH UPDATE

Notice to Healthcare Providers and Public Health Officials: Updated Guidance for the Evaluation of Severe Respiratory Illness
Associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Summary

The Centers for Disease Control and Prevention (CDC) continues to work closely with the World Health Organization (WHO) and other
partners to better understand the public health risks posed by Middle East Respiratory Syndrome Coronavirus (MERS-CoV). To date, no cases
have been reported in the United States. The purpose of this health update is 1) to provide updated guidance to healthcare providers and
state and local health departments regarding who should be tested for MERS-CoV infection, 2) to make them aware of changes to CDC’s
“probable case” definition, and 3) to clarify what specimens should be obtained when testing for MERS-CoV. Please disseminate
this information to infectious disease specialists, intensive care physicians, primary care physicians, and infection preventionists, as
well as to emergency departments and microbiology laboratories.

Background

MERS-CoV, formerly called novel coronavirus,is a beta coronavirus that was first described in September 2012. As of August 12, 2013, 94
laboratory-confirmed cases have been reported to WHO. Of those cases, 49% (46) were fatal. All diagnosed cases were among people who
resided in or traveled from four countries (Kingdom of Saudi Arabia, United Arab Emirates, Qatar, or Jordan) within 14 days of their
symptom onset, or who had close contact with people who resided in or traveled from those countries. Cases with a history of travel from
these countries or contact with travelers from these countries have been identified in residents of France, the United Kingdom, Tunisia,
and Italy. To date, no cases have been reported in the United States. The most up-to-date details about the number of
MERS-CoV cases and deaths by country of residence are on CDC’s MERS website (http://www.cdc.gov/coronavirus/mers/index.html).

Updates to Interim Guidance and Case Definitions

Interim Guidance for Health Professionals: Patients in the U.S. Who Should Be Evaluated

CDC has changed its criteria for who should be evaluated for MERS-CoV. In the previous guidance (HAN 348, dated June 7, 2013), CDC did not recommend MERS-CoV testing for people whose illness could be explained by
another etiology. The new guidance states that, in patients who meet certain clinical and epidemiologic criteria, testing for MERS-CoV
and other respiratory pathogens can be done simultaneously and that positive results for another respiratory pathogen should not
necessarily preclude testing for MERS-CoV.

The new guidance also clarifies recommendations for investigating clusters of severe acute respiratory illness when there is not an
apparent link to a MERS-CoV case. Clusters* of patients with severe acute respiratory illness (e.g., fever and pneumonia
requiring hospitalization) should be evaluated for common respiratory pathogens and reported to local and state health departments. If
the illnesses remain unexplained, testing for MERS-CoV should be considered, in consultation with state and local health
departments.

Case Definitions

CDC has not changed the case definition of a confirmed case, but the criteria for laboratory confirmation have been clarified. CDC has
changed its definition of a probable case so that identification of another etiology does not exclude someone from being classified as a
“probable case.”

CDC may change its guidance about who should be evaluated and considered a case as we learn more about the epidemiology of MERS-CoV
infection and risk of transmission.

Interim Guidance about Testing of Clinical Specimens

CDC recommends collecting multiple specimens from different sites at different times after symptom onset. Lower respiratory specimens are
preferred, but collecting nasopharyngeal and oropharyngeal (NP/OP) specimens, as well as stool and serum, are strongly recommended. This
will increase the likelihood of detecting MERS-CoV infection. For more information, see CDC’s Interim Guidelines for Collecting,
Handling, and Testing Clinical Specimens (http://www.cdc.gov/coronavirus/mers/guidelines-clinical-specimens.html). Many state health department laboratories
are approved for MERS-CoV testing using the CDC rRT-PCR assay. Contact your state health department to notify them of people who should
be evaluated for MERS-CoV and to request MERS-CoV testing. If your state health department is not able to test, contact CDC’s EOC
at 770-488-7100.

The Centers for Disease Control and Prevention (CDC) protects people’s health and safety by preventing and controlling diseases
and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through
strong partnerships with local, national, and international organizations.

************************************

You are receiving this email because you are a registered member of the Delaware Health Alert Network. If you are not a member and would
like to subscribe, please register at https://healthalertde.org

Please note: Some of the files available on this page are in Adobe PDF format which requires Adobe Acrobat Reader. A free copy of Adobe Acrobat Reader can be downloaded directly from Adobe . If you are using an assistive technology unable to read Adobe PDF, please either view the corresponding text only version (if available) or visit Adobe's Accessibility Tools page.